Compare Stocks: GLMD, ADIL, CYCN, and CTXR

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ADIL Adial Pharmaceuticals	$5.03 +0.6%	$4.44	$1.31 ▼ $10.75	$13.23M	1.38	214,584 shs	4,696 shs
CTXR Citius Pharmaceuticals	$0.57 +1.1%	$0.59	$0.47 ▼ $2.19	$15.54M	1	594,674 shs	11,903 shs
CYCN Cyclerion Therapeutics	$3.49 +3.9%	$24.31	$1.03 ▼ $8.48	$16.33M	1.75	96,117 shs	435,914 shs
GLMD Galmed Pharmaceuticals	$4.59 -0.9%	$4.36	$3.29 ▼ $13.20	$4.78M	0.67	52,894 shs	302,067 shs

10 Stocks Powering The Next AI Boom

The AI boom is creating opportunities across semiconductors, cloud computing, enterprise software, infrastructure, cybersecurity, and automation.

Inside this report, you’ll find 10 companies positioned to benefit as artificial intelligence moves from hype to real-world deployment and becomes a core growth driver for corporate America.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ADIL Adial Pharmaceuticals	0.00%	-24.81%	+25.63%	+81.82%	-42.86%
CTXR Citius Pharmaceuticals	-2.27%	-6.73%	-25.87%	+3.72%	-50.87%
CYCN Cyclerion Therapeutics	0.00%	-85.16%	-86.85%	-84.32%	-78.87%
GLMD Galmed Pharmaceuticals	0.00%	+20.00%	+9.91%	-4.41%	-60.70%

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ADIL Adial Pharmaceuticals	$5.03 +0.6%	$4.44	$1.31 ▼ $10.75	$13.23M	1.38	214,584 shs	4,696 shs
CTXR Citius Pharmaceuticals	$0.57 +1.1%	$0.59	$0.47 ▼ $2.19	$15.54M	1	594,674 shs	11,903 shs
CYCN Cyclerion Therapeutics	$3.49 +3.9%	$24.31	$1.03 ▼ $8.48	$16.33M	1.75	96,117 shs	435,914 shs
GLMD Galmed Pharmaceuticals	$4.59 -0.9%	$4.36	$3.29 ▼ $13.20	$4.78M	0.67	52,894 shs	302,067 shs

10 Stocks Powering The Next AI Boom

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ADIL Adial Pharmaceuticals	0.00%	-24.81%	+25.63%	+81.82%	-42.86%
CTXR Citius Pharmaceuticals	-2.27%	-6.73%	-25.87%	+3.72%	-50.87%
CYCN Cyclerion Therapeutics	0.00%	-85.16%	-86.85%	-84.32%	-78.87%
GLMD Galmed Pharmaceuticals	0.00%	+20.00%	+9.91%	-4.41%	-60.70%

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
ADIL Adial Pharmaceuticals	2.40	Hold	$15.63	210.64% Upside
CTXR Citius Pharmaceuticals	2.40	Hold	$5.00	783.39% Upside
CYCN Cyclerion Therapeutics	1.00	Sell	N/A	N/A
GLMD Galmed Pharmaceuticals	1.00	Sell	N/A	N/A

Current Analyst Ratings Breakdown

Latest GLMD, ADIL, CYCN, and CTXR Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
8/19/2026	CTXR Citius Pharmaceuticals	HC Wainwright Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy
8/19/2026	CTXR Citius Pharmaceuticals	Citigroup Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy
8/3/2026	ADIL Adial Pharmaceuticals	Alliance Global Partners Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Initiated Coverage	Buy	$11.00
7/24/2026	CYCN Cyclerion Therapeutics	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Sell (D-)
7/17/2026	ADIL Adial Pharmaceuticals	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Sell (E+)
7/17/2026	GLMD Galmed Pharmaceuticals	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Sell (E+)
6/24/2026	CTXR Citius Pharmaceuticals	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Sell (E+)

(Data available from 9/16/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
ADIL Adial Pharmaceuticals	N/A	N/A	N/A	N/A	$4.75 per share	N/A
CTXR Citius Pharmaceuticals	N/A	N/A	N/A	N/A	$4.29 per share	N/A
CYCN Cyclerion Therapeutics	$2.07M	7.89	N/A	N/A	$2.31 per share	1.51
GLMD Galmed Pharmaceuticals	N/A	N/A	N/A	N/A	$23.04 per share	N/A

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
ADIL Adial Pharmaceuticals	-$7.98M	-$14.73	N/A	N/A	N/A	N/A	-203.87%	-512.41%	11/18/2026 (Estimated)
CTXR Citius Pharmaceuticals	-$37.43M	-$1.67	N/A	N/A	N/A	N/A	-59.57%	-34.47%	N/A
CYCN Cyclerion Therapeutics	-$3.53M	-$1.66	N/A	N/A	N/A	-170.11%	-87.96%	-74.86%	11/11/2026 (Estimated)
GLMD Galmed Pharmaceuticals	-$10.31M	-$15.18	N/A	N/A	N/A	N/A	-73.68%	-60.88%	11/25/2026 (Estimated)

Latest GLMD, ADIL, CYCN, and CTXR Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
9/2/2026	Q2 2026	GLMD Galmed Pharmaceuticals	-$3.12	-$2.86	+$0.26	-$2.86	N/A	N/A
8/14/2026	Q2 2026	ADIL Adial Pharmaceuticals	-$1.0325	-$11.25	-$10.2175	-$11.25	N/A	N/A
8/14/2026	Q3 2026	CTXR Citius Pharmaceuticals	-$0.36	-$0.34	+$0.02	-$0.34	$5.46 million	N/A

Compare Dividends

Company	Annual Payout	Dividend Yield	5-Year Annualized Dividend Growth	Payout Ratio	Years of Consecutive Growth
ADIL Adial Pharmaceuticals	N/A	N/A	N/A	N/A	N/A
CTXR Citius Pharmaceuticals	N/A	N/A	N/A	N/A	N/A
CYCN Cyclerion Therapeutics	N/A	N/A	N/A	N/A	N/A
GLMD Galmed Pharmaceuticals	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
ADIL Adial Pharmaceuticals	N/A	5.63	5.63
CTXR Citius Pharmaceuticals	0.08	0.84	0.40
CYCN Cyclerion Therapeutics	N/A	0.82	0.82
GLMD Galmed Pharmaceuticals	N/A	4.16	4.16

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
ADIL Adial Pharmaceuticals	16.41%
CTXR Citius Pharmaceuticals	16.88%
CYCN Cyclerion Therapeutics	75.62%
GLMD Galmed Pharmaceuticals	76.14%

Insider Ownership

Company	Insider Ownership
ADIL Adial Pharmaceuticals	8.00%
CTXR Citius Pharmaceuticals	4.99%
CYCN Cyclerion Therapeutics	34.30%
GLMD Galmed Pharmaceuticals	19.80%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
ADIL Adial Pharmaceuticals	20	2.63 million	2.42 million	No Data
CTXR Citius Pharmaceuticals	20	27.45 million	26.08 million	Optionable
CYCN Cyclerion Therapeutics	30	4.68 million	3.08 million	No Data
GLMD Galmed Pharmaceuticals	20	1.04 million	836,000	Not Optionable

GLMD, ADIL, CYCN, and CTXR Headlines

Recent News About These Companies

Galmed Pharmaceuticals (NASDAQ:GLMD) Shares Cross Above 50-Day Moving Average - Here's Why

September 10, 2026 | americanbankingnews.com

Galmed Pharma Rebrands To EoCene, Debuts EOCN Ticker As GI Expansion Accelerates; Stock Up

September 9, 2026 | rttnews.com

Galmed Pharmaceuticals Becomes EoCene, Unveiling New Ticker Symbol "EOCN" to Reflect its New Dawn Platform for GI Innovation

September 9, 2026 | prnewswire.com

6 Biotech Stocks In Focus: Modular Medical, Galmed, Pro-Dex, Connect Biopharma & More

September 3, 2026 | rttnews.com

Galmed Pharmaceuticals Shareholders Approve All Proposals at September 3 AGM

September 3, 2026 | tipranks.com

Galmed Pharmaceuticals Ltd.: Galmed Announces Successful First-in-Human Proof-of-Concept Clinical Study Results for Colospan's Novel Intraoperative Tissue Assessment Technology

August 19, 2026 | finanznachrichten.de

Galmed Announces Successful First-in-Human Proof-of-Concept Clinical Study Results for Colospan's Novel Intraoperative Tissue Assessment Technology

August 19, 2026 | prnewswire.com

Galmed Announces First Time Results in Prostate Oncology Studies: Aramchol Demonstrates 3-4 Fold Increase in Cell Death Compared to Enzalutamide (XTANDI®) Alone in Prostate ...

August 17, 2026 | finance.yahoo.com

Galmed Announces First Time Results in Prostate Oncology Studies: Aramchol Demonstrates 3-4 Fold Increase in Cell Death Compared to Enzalutamide (XTANDI®) Alone in Prostate Cancer Models

August 17, 2026 | prnewswire.com

Galmed Pharmaceuticals Develops Oral Film Version of Parkinson's Treatment

July 30, 2026 | finance.yahoo.com

Galmed Pharmaceuticals Drops Yissum License to Sharpen Focus on Colospan and Aramchol

July 29, 2026 | tipranks.com

Galmed Announces Breakthrough Development of Dispersible Film Delivery (ODF), Brain Penetrating formulation of its SCD1 inhibitor Aramchol for Parkinson's Disease, Targeting $6 ...

July 28, 2026 | finance.yahoo.com

Galmed Announces Breakthrough Development of Dispersible Film Delivery (ODF), Brain Penetrating formulation of its SCD1 inhibitor Aramchol for Parkinson's Disease, Targeting $6 Billion Market

July 28, 2026 | prnewswire.com

Galmed Announces the Breakthrough Development of Novel LNP Cardiac Targeted Formulation of its SCD1 inhibitor, Aramchol

July 16, 2026 | prnewswire.com

Galmed and Tissue Dynamics Reveal New Metabolic Target for Cardiac Fibrosis With Aramchol Combo

June 24, 2026 | theglobeandmail.com

Galmed Pharmaceuticals Ltd. Announces Restructured Acquisition Terms for Colospan Ltd., Prioritizing CG-100 European Commercialization and Shareholder Value Protection and ...

June 22, 2026 | finance.yahoo.com

Galmed Pharmaceuticals Ltd. Announces Restructured Acquisition Terms for Colospan Ltd.

June 22, 2026 | prnewswire.com

Galmed Pharmaceuticals Ltd. Ordinary Shares (GLMD)

June 10, 2026 | nasdaq.com

Galmed Pharmaceuticals Ltd.: Galmed Pharmaceuticals to Acquire Colospan to Create a GI-Focused Platform Targeting a $6 Billion Market

June 8, 2026 | finanznachrichten.de

Galmed Pharmaceuticals to Acquire Colospan to Create a GI-Focused Platform Targeting a $6 Billion Market

June 8, 2026 | prnewswire.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

GLMD, ADIL, CYCN, and CTXR Company Descriptions

Adial Pharmaceuticals NASDAQ:ADIL

$5.03 +0.03 (+0.60%)

As of 10:17 AM Eastern

Adial Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the development of therapeutics for the treatment or prevention of addiction and related disorders. Its lead product is AD04, a serotonin-3 antagonist, which is in Phase III clinical trial for the treatment of alcohol use disorder. The company also focuses on developing drug candidates for non-opioid pain reduction and other diseases and disorders. Adial Pharmaceuticals, Inc. was founded in 2010 and is based in Charlottesville, Virginia.

Citius Pharmaceuticals NASDAQ:CTXR

$0.57 +0.01 (+1.05%)

As of 10:14 AM Eastern

Citius Pharmaceuticals, Inc., a late-stage pharmaceutical company, engages in the development and commercialization of critical care products focusing on oncology products, anti-infectives products in adjunct cancer care, prescription products, and stem cell therapy. It is developing five proprietary products comprising LYMPHIR, an engineered IL-2 diphtheria toxin fusion protein for the treatment of patients with persistent or recurrent cutaneous T-cell lymphoma, which is in Phase 3 clinical trial; Mino-Lok, an antibiotic lock solution to treat patients with catheter-related bloodstream infections by salvaging the infected catheter, which is in Phase 3 clinical trial; Halo-Lido, a corticosteroid-lidocaine topical formulation that intends to provide anti-inflammatory and anesthetic relief to persons suffering from hemorrhoids that is in clinical Phase 2b trial; Mino-Wrap, a liquifying gel-based wrap for reduction of tissue expander infections following breast reconstructive surgeries; and NoveCite, a mesenchymal stem cell therapy for the treatment of acute respiratory disease syndrome. The company was founded in 2007 and is headquartered in Cranford, New Jersey.

Cyclerion Therapeutics NASDAQ:CYCN

$3.49 +0.13 (+3.87%)

Closing price 09/8/2026

Extended Trading

$3.49 0.00 (0.00%)

As of 09/8/2026 07:42 PM Eastern

Cyclerion Therapeutics, Inc., a biopharmaceutical company, develops treatments for serious diseases. It is developing Olinciguat, an orally administered vascular soluble guanylate cyclase (sGC) stimulator, which is in Phase 2 clinical trial to out-license for cardiovascular diseases; and Praliciguat, a systemic sGC stimulator that is licensed to Akebia Therapeutics, Inc. for the treatment of rare kidney disease. The company was incorporated in 2018 and is headquartered in Cambridge, Massachusetts.

Galmed Pharmaceuticals NASDAQ:GLMD

$4.59 -0.04 (-0.86%)

Closing price 09/9/2026

Extended Trading

$4.59 0.00 (0.00%)

As of 09/9/2026 07:56 PM Eastern

Galmed Pharmaceuticals Ltd., a biopharmaceutical company, focuses on the development of therapeutics for the treatment of liver diseases. It develops Aramchol, an oral therapy, which is in Phase III study for the treatment of non-alcoholic steato-hepatitis (NASH) in patients with overweight or obesity and who are pre-diabetic or type-II-diabetes mellitus. The company also evaluates Aramchol through ARRIVE Study, a Phase IIa clinical trial with HIV-associated non-alcoholic fatty liver disease and lipodystrophy. In addition, it engages in the development of Amilo-5MER, a 5 amino acid synthetic peptide methionine, threonine, alanine, aspartic acid, and valine. It has a license agreement with Samil Pharma. Co., Ltd. for the commercialization of Aramchol in the Republic of Korea; and a collaboration agreement with OnKai for its AI platform. Galmed Pharmaceuticals Ltd. was founded in 2000 and is headquartered in Tel Aviv, Israel.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest GLMD, ADIL, CYCN, and CTXR Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest GLMD, ADIL, CYCN, and CTXR Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

GLMD, ADIL, CYCN, and CTXR Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

GLMD, ADIL, CYCN, and CTXR Company Descriptions

Adial Pharmaceuticals NASDAQ:ADIL

Citius Pharmaceuticals NASDAQ:CTXR

Cyclerion Therapeutics NASDAQ:CYCN

Galmed Pharmaceuticals NASDAQ:GLMD

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest GLMD, ADIL, CYCN, and CTXR Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest GLMD, ADIL, CYCN, and CTXR Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

GLMD, ADIL, CYCN, and CTXR Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

GLMD, ADIL, CYCN, and CTXR Company Descriptions

Adial Pharmaceuticals NASDAQ:ADIL

Citius Pharmaceuticals NASDAQ:CTXR

Cyclerion Therapeutics NASDAQ:CYCN

Galmed Pharmaceuticals NASDAQ:GLMD

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools